Screening for T1D by either genetic or immunologic methods has led to the possibility of preventing disease in susceptible individuals. Both primary and secondary prevention trials are underway or recently completed. The outcome of TRIGR and DIPP will shed light on the effect of these primary prevention strategies within the next few years. The preliminary results of two large secondary prevention trials, the DPT-1 and ENDIT, have not been encouraging. In both cases, late intervention in the disease process, or incorrect drug dose, route of administration, or frequency, may help explain the negative results. Further secondary prevention trials are being considered. Some evidence suggests that up to 20% of patients diagnosed with type 2 diabetes mellitus have islet cell-specific autoimmunity, leading to the definition of a new form of diabetes referred to as type 1.5 diabetes mellitus, slowly progressive insulin-dependent diabetes mellitus, noninsulin requiring diabetes, or, more commonly, latent autoimmune diabetes in adults . If such patients truly have a slowly developing form of T1D, the actual number of individuals with T1D would significantly increase. In light of such considerations, efficient prediction and prevention strategies are needed now more than ever. Numerous studies to improve our knowledge of the disease are in progress and may shed light on new prediction and prevention strategies.
|Original language||English (US)|
|Number of pages||18|
|Journal||Endocrinology and Metabolism Clinics of North America|
|State||Published - Mar 2004|
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism